Cambridge Investment Research Advisors
PHAT icon

Cambridge Investment Research Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,300
Closed -$552K – 3172
2021
Q2 		$552K Hold
16,300
– – ﹤0.01% 1969
2021
Q1 		$612K Hold
16,300
– – ﹤0.01% 1753
2020
Q4 		$541K Hold
16,300
– – ﹤0.01% 1720
2020
Q3 		$598K Buy
+16,300
New +$565K ﹤0.01% 1493

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Cambridge Investment Research Advisors's PHAT Position: Q3 2021 in Review

Cambridge Investment Research Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q3 2021, closing a stake of 16,300 shares — an estimated $552K sold.

Cambridge Investment Research Advisors first reported a position in PHAT in Q3 2020 and held it in 4 quarters. The position peaked at $612K in Q1 2021. 84 funds tracked by Wall St. Rank hold PHAT as of Q3 2021.

  • Cambridge Investment Research Advisors reported no remaining Phathom Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 16,300 Phathom Pharmaceuticals shares in Q3 2021, an estimated $552K.
  • Cambridge Investment Research Advisors first reported a position in Phathom Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Phathom Pharmaceuticals position peaked at $612K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.